Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Unresectable Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Decitabine and Cedazuridine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab
Sponsor: National Cancer Institute (NCI)